FIELD: medicine; pharmacology.
SUBSTANCE: group of inventions relates to the field of medicine and pharmacology, namely to a composition for the treatment and/or prevention of influenza and acute respiratory viral diseases, that includes 2-(imidazole-4-yl)-ethanamide of pentanedioic-1,5 acid and N,N'-bis-[2-(1H-imidazole-4-yl)ethyl]pentanediamide and/or their pharmaceutically acceptable salts, wherein N,N'-bis-[2-(1H-imidazole-4-yl)ethyl]pentanediamide is contained in an amount from 0.01 to 0.12 wt. %; as well as to a pharmaceutical composition containing the specified composition and at least one pharmaceutically acceptable carrier; a medicinal product in the form of pills, capsules or syrup placed in a pharmaceutically acceptable package containing the specified composition or composition in an effective amount; a medicinal form in the form of pills, capsules or syrup placed in a pharmaceutically acceptable package containing the specified makeup, composition or drug in an effective amount; the use of the specified composition for the treatment and/or prevention of influenza and acute respiratory viral diseases; the use of the specified composition, drug or finished dosage form for the treatment and/or prevention of influenza and acute respiratory viral diseases.
EFFECT: group of inventions provides an expansion of the arsenal of antiviral agents and means for the treatment and/or prevention of respiratory tract diseases, as well as an increase in the stability of 2-(imidazole-4-yl)-ethanamide pentanedioic-1,5 acid.
14 cl, 4 tbl, 6 ex
